肝酶升高并非别嘌醇剂量上调的障碍:一项观察性队列研究
别嘌醇剂量与肝酶升高无关(P=0.193),饮酒为独立危险因素,他汀使用似有保护作用;轻度-中度转氨酶升高时别嘌醇可安全上调。
要点
- 痛风患者起始别嘌醇后轻度无症状AST/ALT升高常见,不因剂量上调而加重。
- 饮酒是肝酶升高的独立危险因素,他汀使用似有保护作用。
- 轻度-中度转氨酶升高时别嘌醇可安全维持或上调剂量。
核心结论
- 痛风患者中轻度无症状AST/ALT升高常见,且不受别嘌醇剂量上调影响。
- 饮酒是肝酶升高的独立危险因素,而他汀使用似有保护作用。
- 尽管存在轻度-中度血清转氨酶升高,别嘌醇仍可安全上调剂量。
主要发现
- 第2次访视时19例转氨酶升高患者中18例维持或增加别嘌醇剂量,后续访视中27.8%稳定、11.1%改善、33.3%恢复正常,无一例恶化。
- 多变量分析显示饮酒(校正OR 3.52,95%CI 1.41-8.79)和他汀未使用(校正OR 3.41,95%CI 1.04-11.17)是转氨酶升高的独立预测因素。
- 较高的别嘌醇剂量与肝酶升高无关(P=0.193)。
关键数值与推荐
- 转氨酶升高分级:AST或ALT低于正常上限2倍为轻度,2-3倍为中度,超过3倍为重度。
临床怎么用
- 对于基线转氨酶正常的痛风患者,别嘌醇剂量上调时无需因轻度-中度AST/ALT升高而停药。
- 应关注患者饮酒情况,饮酒者肝酶升高风险增加。
- 他汀使用可能与较低的肝酶升高风险相关。
局限性
- 观察性设计无法排除混杂因素,因果推断受限。
- 研究人群以男性为主(95.3%),结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Routine liver enzyme monitoring is advocated for while on allopurinol, but supporting guidance is lacking. We assessed the incidence and factors associated with elevated liver enzyme levels in patients with gout commenced on allopurinol. METHODS: One hundred and fifty patients with gout and normal baseline serum aminotransferases initiated on allopurinol were followed prospectively over three visits. Raised transaminase levels were defined as mild, moderate, or severe if aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels were raised less than two, two to three, or more than three times above upper normal limits, respectively. Predictors of AST/ALT elevation were assessed using generalized estimating equations. RESULTS: Mean age was 56.6 years, and 95.3% were men. Median follow-up was 33.5 (interquartile range 22.8-53.1) weeks. A total of 32 (21.5%) drank alcohol, 43 (28.9%) were obese, and 11 (7.3%) had metabolic dysfunction-associated steatotic liver disease. Thirty (20.0%) developed raised AST/ALT levels during follow-up, the majority (86.7%) being mild, while none were severe. Allopurinol was maintained or increased in 18 out of 19 patients with raised serum aminotransferase levels at visit 2. Their elevated AST/ALT levels remained stable (27.8%), improved (11.1%), or resolved (33.3%) at subsequent visit. None had worsening AST/ALT levels. Multivariate analysis revealed that alcohol consumption (adjusted odds ratio [OR] 3.52, 95% confidence interval [CI] 1.41-8.79) and statin nonuse (adjusted OR 3.41, 95% CI 1.04-11.17) were independent predictors of raised transaminase levels. Higher allopurinol dose was not associated with development of liver enzyme elevation (P = 0.193). CONCLUSION: Mild asymptomatic AST/ALT elevation is common among patients with gout and is not influenced by allopurinol dose escalation. Alcohol consumption was an independent risk factor for elevated liver enzyme levels, whereas statin use appeared protective. Allopurinol can be safely escalated despite mild-moderate serum aminotransferase elevation.
引用
- Tang MS, Yap QV, Cheung PPM, et al. Elevated Liver Enzymes Is Not an Impediment to Allopurinol Dose Escalation: An Observational Cohort Study. Arthritis Care Res (Hoboken). 2026. PMID: 42703742. doi:10.1002/acr.80157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。